Hong Tao, Li Jiao-Yang, Wang Ya-Di, Qi Xiao-Yan, Liao Zhe-Zhen, Bhadel Poonam, Ran Li, Yang Jing, Yan Bin, Liu Jiang-Hua, Xiao Xin-Hua
Department of Metabolism and Endocrinology, The First Affiliated Hospital of University of South China, Hengyang 421001, Hunan, China.
Int J Endocrinol. 2021 Mar 2;2021:6622129. doi: 10.1155/2021/6622129. eCollection 2021.
Asprosin, a new adipocytokine, has reportedly been associated with glucose release, dyslipidemia, and insulin resistance (IR). However, the relationship of asprosin with metabolic syndrome (MetS) remains unknown. This study aimed to investigate serum asprosin levels in MetS as well as their association with various metabolic parameters in humans.
A total of 131 consecutive patients with MetS, and 162 age-matched, healthy subjects were recruited for this study. Serum asprosin concentrations were determined using the enzyme-linked immunosorbent assay. Lipid profile, glucose, insulin, and inflammatory markers were also measured.
Serum asprosin levels were higher in subjects with MetS (23.52 [16.70, 32.05] ng/mL) than in controls (16.70 [12.87, 22.38] ng/mL; < 0.01), and they showed an increasing trend with increasing numbers of metabolic components ( for trend < 0.01). In all studied subjects, serum asprosin levels were positively correlated with body mass index, waist circumference, triglycerides, fasting plasma glucose, 2-hour plasma glucose, fasting insulin, homeostatic model assessment of insulin resistance (HOMA-IR) index, interleukin-6, and monocyte chemoattractant protein-1 and negatively correlated with high-density lipoprotein cholesterol ( < 0.05). In multiple linear regression, asprosin was independently and positively correlated with triglyceride and HOMA-IR ( < 0.05). Binary logistic regression revealed that asprosin was independently and positively correlated with the occurrence of MetS and IR, even after controlling for anthropometric variables, lipid profiles, and inflammatory markers.
Asprosin is a potential metabolic-related adipokine and may be related to IR and MetS. This trial was registered with ChiCTR, ChiCTR1800018347.
据报道，一种新的脂肪细胞因子——促血糖素与葡萄糖释放、血脂异常和胰岛素抵抗（IR）有关。然而，促血糖素与代谢综合征（MetS）的关系仍不清楚。本研究旨在调查代谢综合征患者的血清促血糖素水平及其与人体各种代谢参数的关联。
本研究共纳入了131例连续的代谢综合征患者和162例年龄匹配的健康受试者。采用酶联免疫吸附测定法测定血清促血糖素浓度。同时还测量了血脂、血糖、胰岛素和炎症标志物。
代谢综合征患者的血清促血糖素水平（23.52[16.70，32.05]ng/mL）高于对照组（16.70[12.87，22.38]ng/mL；P<0.01），且随着代谢组分数量的增加呈上升趋势（趋势P<0.01）。在所有研究对象中，血清促血糖素水平与体重指数、腰围、甘油三酯、空腹血糖、餐后2小时血糖、空腹胰岛素、胰岛素抵抗稳态模型评估（HOMA-IR）指数、白细胞介素-6和单核细胞趋化蛋白-1呈正相关，与高密度脂蛋白胆固醇呈负相关（P<0.05）。在多元线性回归中，促血糖素与甘油三酯和HOMA-IR独立正相关（P<0.05）。二元逻辑回归显示，即使在控制了人体测量变量、血脂谱和炎症标志物后，促血糖素仍与代谢综合征和胰岛素抵抗的发生独立正相关。
促血糖素是一种潜在的与代谢相关的脂肪因子，可能与胰岛素抵抗和代谢综合征有关。本试验已在中国临床试验注册中心注册，注册号为ChiCTR1800018347。
